- Nachrichtendetail
-
14.05.2024 07:30:53 - EQS-News: PharmaSGP continues dynamic business development with significant revenues growth in Q1 2024
===
EQS-News: PharmaSGP Holding SE / Key word(s): Quarter Results/Preliminary Results
PharmaSGP continues dynamic business development with significant revenues growth in Q1 2024
2024-05-14 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
PharmaSGP continues dynamic business development with significant revenues growth in Q1 2024
Gräfelfing, May 14, 2024 - German OTC pharmaceutical company PharmaSGP Holding SE continued the positive business
development of 2023 in the first quarter of 2024 and achieved an increase in revenues of 25.6% to EUR30.1 million
(prior-year quarter: EUR24.0 million) based on preliminary, unaudited figures. Compared to the previous year, adjusted
earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) rose from EUR7.0 million to EUR8.9 million
in the first three months of 2024. The resulting adjusted EBITDA margin increased quarter-on-quarter to 29.4%
(prior-year quarter: 29.2%).
CEO Natalie Weigand comments: "After an outstanding year 2023 and significantly faster growth than the market, we are
very proud to be able to continue this development in 2024. Accordingly, we have further strengthened our position as a
fast-growing OTC consumer health company in Europe in the first three months of 2024 thanks to our well-proven platform
model and effective marketing strategies."
CFO Michael Rudolf adds: "The revenues figures for the first quarter of 2024 reflect in particular PharmaSGP's
potential in foreign markets. As expected, the adjusted EBITDA margin of 29.4% was slightly higher than in the
prior-year quarter. With the revenues and earnings margin achieved in the first three months of 2024, we see ourselves
well on track for another year of profitable growth."
In the current financial year 2024, revenues are expected to be in a range between EUR107.0 million and EUR112.0 million.
The Management Board expects adjusted EBITDA to increase to between EUR35.0 million and EUR38.0 million. This corresponds
to an adjusted EBITDA margin of 32.7% to 33.9%.
PharmaSGP will publish its full statement for the first three months of 2024 on May 28, 2024.
OVERVIEW OF PRELIMINARY YEAR-ON-YEAR FIGURES
CONTACT
===
cometis AG Claudius Krause Phone: +49-611-20585528 Email: ir@pharmasgp.com
ABOUT PHARMASGP HOLDING SE
PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.
The Company's core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX^® for rheumatic pain and Restaxil^® for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan^®, Formigran ^®, Spalt^® and Kamol^®, thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe. In 2023, PharmaSGP generated revenues of EUR101.1 million at an adjusted EBITDA margin of 33.7%.
In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP's product offering, increase PharmaSGP's European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.
-----------------------------------------------------------------------------------------------------------------------
2024-05-14 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
-----------------------------------------------------------------------------------------------------------------------
===
Lochhamer Schlag 1
82166 Gräfelfing
Germany
Munich, Tradegate Exchange
EQS News ID: 1901587
End of News EQS News Service
===
1901587 2024-05-14 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1901587&application_name=news
END) Dow Jones Newswires
May 14, 2024 01:30 ET (05:30 GMT)
EQS-News: PharmaSGP Holding SE / Key word(s): Quarter Results/Preliminary Results
PharmaSGP continues dynamic business development with significant revenues growth in Q1 2024
2024-05-14 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
PharmaSGP continues dynamic business development with significant revenues growth in Q1 2024
Gräfelfing, May 14, 2024 - German OTC pharmaceutical company PharmaSGP Holding SE continued the positive business
development of 2023 in the first quarter of 2024 and achieved an increase in revenues of 25.6% to EUR30.1 million
(prior-year quarter: EUR24.0 million) based on preliminary, unaudited figures. Compared to the previous year, adjusted
earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) rose from EUR7.0 million to EUR8.9 million
in the first three months of 2024. The resulting adjusted EBITDA margin increased quarter-on-quarter to 29.4%
(prior-year quarter: 29.2%).
CEO Natalie Weigand comments: "After an outstanding year 2023 and significantly faster growth than the market, we are
very proud to be able to continue this development in 2024. Accordingly, we have further strengthened our position as a
fast-growing OTC consumer health company in Europe in the first three months of 2024 thanks to our well-proven platform
model and effective marketing strategies."
CFO Michael Rudolf adds: "The revenues figures for the first quarter of 2024 reflect in particular PharmaSGP's
potential in foreign markets. As expected, the adjusted EBITDA margin of 29.4% was slightly higher than in the
prior-year quarter. With the revenues and earnings margin achieved in the first three months of 2024, we see ourselves
well on track for another year of profitable growth."
In the current financial year 2024, revenues are expected to be in a range between EUR107.0 million and EUR112.0 million.
The Management Board expects adjusted EBITDA to increase to between EUR35.0 million and EUR38.0 million. This corresponds
to an adjusted EBITDA margin of 32.7% to 33.9%.
PharmaSGP will publish its full statement for the first three months of 2024 on May 28, 2024.
OVERVIEW OF PRELIMINARY YEAR-ON-YEAR FIGURES
Consolidated figures (in EUR million) Q1 2024 Q1 2023 ? Revenues 30.1 24.0 +25.6% Adjusted EBITDA 8.9 7.0 +26.5% Unadjusted EBITDA 8.7 7.0 +23.5% Adjusted EBITDA margin 29.4% 29.2% Unadjusted EBITDA margin 28.7% 29.2%
Revenues by region (in EUR million) Q1 2024 Q1 2023 ? Germany 20.8 17.9 +16.1% Italy 5.3 2.9 +80.2% Austria 3.2 2.1 +49.7% Other European countries 0.9 1.0 -15.5%
Revenues share by region Q1 2024 Q1 2023 Germany 69% 75% Italy 18% 12% Austria 11% 9% Other European countries 2% 4%
Revenues by product category (in EUR million) Q1 2024 Q1 2023 ? Health Brands 29.0 23.2 +24.8% Beauty Brands 1.1 0.8 +42.0%
CONTACT
===
cometis AG Claudius Krause Phone: +49-611-20585528 Email: ir@pharmasgp.com
ABOUT PHARMASGP HOLDING SE
PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.
The Company's core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX^® for rheumatic pain and Restaxil^® for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan^®, Formigran ^®, Spalt^® and Kamol^®, thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe. In 2023, PharmaSGP generated revenues of EUR101.1 million at an adjusted EBITDA margin of 33.7%.
In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP's product offering, increase PharmaSGP's European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.
-----------------------------------------------------------------------------------------------------------------------
2024-05-14 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
-----------------------------------------------------------------------------------------------------------------------
===
Language: English Company: PharmaSGP Holding SE
Lochhamer Schlag 1
82166 Gräfelfing
Germany
E-mail: ir@pharmasgp.com Internet: https://pharmasgp.com ISIN: DE000A2P4LJ5 WKN: A2P4LJ Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf,
Munich, Tradegate Exchange
EQS News ID: 1901587
End of News EQS News Service
===
1901587 2024-05-14 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1901587&application_name=news
END) Dow Jones Newswires
May 14, 2024 01:30 ET (05:30 GMT)
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
PHARMASGP HOLDING SE O.N. | A2P4LJ | Xetra | 23,000 | 27.06.24 10:23:59 | ±0,000 | ±0,00% | 22,600 | 23,200 | 22,800 | 23,000 |
